International Clinical Trial: Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Engineered Mitochondrial Vaccine as Neoadjuvant and Adjuvant Therapy for Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm, Single-Center Clinical Study

Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123925) titled 'Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Engineered Mitochondrial Vaccine as Neoadjuvant and Adjuvant Therapy for Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm, Single-Center Clinical Study' on May 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital, Sichuan University

Condition: locally advanced head and neck squamous cell carcinoma

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-05-01

Target Sample Size: Intervention Group:9;

Countries of Recruitment: China

To know more, visit ht...